Commentary criticizes Robert F. Kennedy Jr. and his direction of the FDA for replacing evidence-based medicine with what critics call arrogance-based approaches, including controversial peptide treatments and other non-traditional medical interventions. Critics argue the agency has abandoned scientific peer review standards under his leadership.
FDA scientists are advising against allowing widespread use of experimental peptide injections, conflicting with Health Secretary Robert F. Kennedy Jr.'s stance that people should have freedom to experiment. Some FDA advisory panel members reportedly sell the same peptides for approximately $200 per injection, raising concerns about potential conflicts of interest.
Reports on FDA panel approval of unapproved peptide injections favored by RFK Jr. were mixed with an unrelated post about the European Central Bank consulting on new currency designs. These are two separate stories conflated in a single grab-bag cluster.